Related references
Note: Only part of the references are listed.Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice
Hirohiko Kamiyama et al.
CLINICAL CANCER RESEARCH (2013)
Everolimus for the treatment of pancreatic neuroendocrine tumors
Georg Feldmann et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma
Natalie Cook et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Patient-derived tumour xenografts as models for oncology drug development
John J. Tentler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Pharmacokinetics, Distribution, and Metabolism of [14C]Sunitinib in Rats, Monkeys, and Humans
Bill Speed et al.
DRUG METABOLISM AND DISPOSITION (2012)
Sunitinib In Advanced, Well Differentiated Pancreatic Neuroendocrine Tumors
Emma D. Deeks et al.
BIODRUGS (2011)
Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression
Marcela Franco et al.
BLOOD (2011)
First-Line Chemotherapy With Capecitabine and Temozolomide in Patients With Metastatic Pancreatic Endocrine Carcinomas
Jonathan R. Strosberg et al.
CANCER (2011)
Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies
Tara C. Gangadhar et al.
CLINICAL CANCER RESEARCH (2011)
An Algorithm for the Management of Hypertension in the Setting of Vascular Endothelial Growth Factor Signaling Inhibition
M. Sitki Copur et al.
CLINICAL COLORECTAL CANCER (2011)
Use of a Mouse Model of Pancreatic Neuroendocrine Tumors to Find Pericyte Biomarkers of Resistance to Anti-angiogenic Therapy
M. Franco et al.
HORMONE AND METABOLIC RESEARCH (2011)
New Insights into Molecular Mechanisms of Sunitinib-Associated Side Effects
Guadalupe Aparicio-Gallego et al.
MOLECULAR CANCER THERAPEUTICS (2011)
TRANSLATIONAL MEDICINE Cancer lessons from mice to humans
David Tuveson et al.
NATURE (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
Yuchen Jiao et al.
SCIENCE (2011)
Pharmacokinetics of sunitinib malate in subjects with hepatic impairment
Carlo L. Bello et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Evaluation of the Combination 5-Fluorouracil, Dacarbazine, and Epirubicin in Patients With Advanced Well-Differentiated Neuroendocrine Tumors
Thomas Walter et al.
CLINICAL COLORECTAL CANCER (2010)
Dramatic efficacy of chemotherapy with 5-fluoro-uracile and dacarbazine in a patient with metastatic glucagonoma and cardiac insufficiency
L. de Mestier et al.
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE (2010)
Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal Function
Reza Khosravan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
NANETS Treatment Guidelines Well-Differentiated Neuroendocrine Tumors of the Stomach and Pancreas
Matthew H. Kulke et al.
PANCREAS (2010)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species
Joshua Oe Haznedar et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients
Brett E. Houk et al.
CLINICAL CANCER RESEARCH (2009)
O-6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors
Matthew H. Kulke et al.
CLINICAL CANCER RESEARCH (2009)
Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2
Suneet Shukla et al.
DRUG METABOLISM AND DISPOSITION (2009)
Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors
Marlies H. G. Langenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Chemotherapy in Patients with Neuroendocrine Tumors
Barbro Eriksson et al.
NEUROENDOCRINOLOGY (2009)
Brief Report: Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449.
Charles M. Rudin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
Kenneth P. Olive et al.
SCIENCE (2009)
Inhibition of vascular endothelial growth factor-A signaling induces hypertension: Examining the effect of cediranib (Recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant anti hypertensive therapy
Jon O. Curwen et al.
CLINICAL CANCER RESEARCH (2008)
Sex-specific differences in CYP450 isoforms in humans
Marissa J. Scandlyn et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2008)
Targeting vascular endothelial growth factor in advanced carcinoid tumor: A random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alfa-2b
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
One hundred years after Carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Activity of sunitinib in patients with advanced neuroendocrine tumors
Matthew H. Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Interventional treatment of neuroendocrine liver metastases
U. Knigge et al.
SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND (2008)
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period
Carolyn D. Britten et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors
Sara Ekeblad et al.
CLINICAL CANCER RESEARCH (2007)
Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors
Jun Zhang et al.
CANCER (2007)
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers
Georg Feldmann et al.
CANCER RESEARCH (2007)
Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
Vicki L. Goodman et al.
CLINICAL CANCER RESEARCH (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors
Eduardo Vilar et al.
ENDOCRINE-RELATED CANCER (2007)
Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas
Marie-Louise Fjallskog et al.
ACTA ONCOLOGICA (2007)
Molecular basis for sunitinib efficacy and future clinical development
Sandrine Faivre et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension
Murat Dincer et al.
ANNALS OF PHARMACOTHERAPY (2006)
Distribution of sunitinib and its active metabolite in brain and spinal cord tissue following oral or intravenous administration in rodents and monkeys
S. Patyna et al.
EJC SUPPLEMENTS (2006)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Michael R. Mancuso et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases
Dong Wook Kim et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects
Carlo L. Bello et al.
ANTI-CANCER DRUGS (2006)
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors
MH Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
S Faivre et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
O Casanovas et al.
CANCER CELL (2005)
Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma
P Marzola et al.
CLINICAL CANCER RESEARCH (2005)
A multitargeted, metronomic, and maximum-tolerated dose chemo-switch regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer
K Pietras et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression
A Couvelard et al.
BRITISH JOURNAL OF CANCER (2005)
Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor
AM Morimoto et al.
ONCOGENE (2004)
Quantitation of SU11248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction
S Barattè et al.
JOURNAL OF CHROMATOGRAPHY A (2004)
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas
MA Kouvaraki et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors
AD McCollum et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2004)
Rhebbing up mTOR - New insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis
DJ Kwiatkowski
CANCER BIOLOGY & THERAPY (2003)
Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression
DE Hansel et al.
MODERN PATHOLOGY (2003)
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
G Bergers et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
AM O'Farrell et al.
BLOOD (2003)
Discovery of 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase
L Sun et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
LJ Murray et al.
CLINICAL & EXPERIMENTAL METASTASIS (2003)
Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis
JA Joyce et al.
CANCER CELL (2003)
Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: Correlation with microvessel density and clinicopathologic features
S La Rosa et al.
HUMAN PATHOLOGY (2003)
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis
M Inoue et al.
CANCER CELL (2002)
Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors
KA Yao et al.
SURGERY (2001)
Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282
RK Ramanathan et al.
ANNALS OF ONCOLOGY (2001)
Share Paper
